Iconovo sets ambitious financial targets for 2026

Iconovo AB (publ), which develops complete inhalation products for a global market, today announces its five-year goals for the business. By 2026, the company expects to achieve sales of SEK 200 million. The target for operating profit is SEK 100 million, corresponding to an operating margin of 50%.

Iconovo and Respiratorius sign agreement for development of inhalation product to treat COPD

Iconovo AB (publ), which develops complete inhalation products for a global market, and Respiratorius AB (publ), which develops drug candidates for the treatment of COPD, and other common diseases, announced today that they have signed an agreement for the development of an inhalation formulation as well as an inhalation product for phase I studies for Respiratorius drug candidate RES030-085 within the RESP9000 project for the treatment of COPD and severe asthma.

INVITATION TO ICONOVO’S VIRTUAL CAPITAL MARKETS DAY

Iconovo AB (publ) hereby invites analysts, investors and media to its virtual Capital Markets Day (CMD) on Wednesday May 26, at 13:00–15:30 CET.

Iconovo extends agreement with Amneal for generic Symbicort to cover key markets U.S. and China, as well as Nordic sales rights

Iconovo AB (publ), which develops complete inhalation products for a global market, today announced that its collaboration with the U.S. pharmaceutical company Amneal is expanding to include additional territories that lead to the announced potential for future annual royalty income more than doubling to USD 13.2 – 26.4 million. Iconovo has also acquired the license to sell Amneal's generic versions of Symbicort® in the Nordic region with the potential to generate revenues between USD 9.5 – 11.9 million.

Abbreviated interim report January – March 2021

Strategic innovation generates new agreements

Iconovo´s new inhaler ICOpre to be presented at RDD 2021 workshop

Iconovo´s new prefilled dual cavity dry powder inhaler will be publicly presented for the first time at RDD 2021 (May 4 – 7th). The design, different features and the development process of ICOpre® will be displayed at a workshop at the meeting. Iconovo explains how an integrated process can accelerate the product development to arrive at a complete inhalation product bioequivalent to Ellipta® including both the inhaler and a powder formulation. Iconovo applies a parallel development process for all generic Ellipta products and plans to out-license the whole portfolio of generic Ellipta products in ICOpre.

First granted ICOone® patent in the United States

United States Patent and Trademark Office has announced the intention to grant a patent (Notice of Allowance) regarding Iconovo’s inhalation device ICOone. Iconovo has previously granted ICOone patents in Sweden, Europe (EPO) and India. The new patent covers a unit dose inhaler used in Iconovo’s two innovative customer projects with Oxytocin and Covid-19 vaccine.

Iconovo signs agreement with ISR for the development of inhaled covid-19 vaccine

Iconovo AB (publ), a company developing complete inhalation products for a global market, today announced that it has signed an agreement with the immunotherapy company Immune System Regulation AB (ISR), an affiliate to ISR Immune System Regulation Holding AB (publ), for the development of an inhaled covid-19 vaccine in Iconovo’s inhaler ICOone®. The agreement is Iconovo’s second agreement within its newest strategic area innovative inhalation projects and confirms the suitability of ICOone to be used also for vaccines.

First granted ICOone® patent in India

Iconovo AB (publ) has been granted its first patent in India on the inhalation platform ICOone®. Iconovo has previously granted ICOone® patents in Europe (EPO) and have several patents pending in USA, India, China and Japan.

Abbreviated interim report january – december 2020

50 percent growth in 2020 and ambitious goals for the future